iSpecimen (NASDAQ:ISPC) PT Lowered to $4.25

iSpecimen (NASDAQ:ISPCGet Rating) had its price target reduced by equities research analysts at EF Hutton Acquisition Corp I from $5.50 to $4.25 in a report issued on Friday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. EF Hutton Acquisition Corp I’s target price indicates a potential upside of 122.51% from the company’s current price.

iSpecimen Price Performance

iSpecimen stock remained flat at $1.91 during trading hours on Friday. 6,986 shares of the company’s stock traded hands, compared to its average volume of 46,357. iSpecimen has a 1 year low of $1.51 and a 1 year high of $28.98. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.12. The stock has a 50 day moving average of $2.25 and a 200-day moving average of $2.87.

iSpecimen (NASDAQ:ISPCGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.30) EPS for the quarter. iSpecimen had a negative return on equity of 36.25% and a negative net margin of 84.89%. The business had revenue of $2.34 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ISPC. Jane Street Group LLC bought a new stake in iSpecimen in the 1st quarter valued at approximately $56,000. Grimes & Company Inc. increased its stake in iSpecimen by 78.3% in the 2nd quarter. Grimes & Company Inc. now owns 62,014 shares of the company’s stock valued at $135,000 after buying an additional 27,243 shares during the last quarter. Teton Advisors Inc. bought a new stake in iSpecimen during the 1st quarter worth about $215,000. Finally, BlackRock Inc. boosted its stake in shares of iSpecimen by 903.6% during the 1st quarter. BlackRock Inc. now owns 71,175 shares of the company’s stock worth $382,000 after buying an additional 64,083 shares during the last quarter. Institutional investors own 4.20% of the company’s stock.

About iSpecimen

(Get Rating)

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.

Further Reading

Stock Target Advisor logo

Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.